BioSpace News Archive

The new entity, funded by $55 million from the BCBS businesses, was born as a response to the high costs of prescription medicines in the United States and concerns about the overall affordability of health care.

Investigators at the Case Western University School of Medicine identified a previously unknown gene and the resultant protein that may potentially slow the progress of Alzheimer’s disease.

That would accelerate the company’s “decarbonization” plan by more than a decade.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Eisai Co., Ltd. has obtained the approvals of supplementary new drug applications in Japan for its in-house developed antiepileptic drug Fycompa for an additional indication for monotherapy of partial-onset seizures and an additional indication for partial-onset seizures in pediatric patients aged 4 years and older, as well as a new fine granule formulation.

Vivante Health, the leader in digital medicine for gut health and disease, proudly announced Stacy Hodgins has joined the company as Chief Analytics Officer.

Trust Transparency Center (TTC) is pleased to announce the formation of the Ingredient Transparency Center (ITC).

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that Dr. André P. Boulet, president and CEO and Dr. Nathalie Boucher, Director Research of the Corporation, will present at the World Conference on Ageing and Gerontology, which is being held in Lisbon, Portugal from August 10-11, 2020.

Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its portfolio investment company Kannalife, Inc.

Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the fourth quarter and full-year ended December 31, 2019 on Monday, February 10, 2020 after the market close.